DBPapers
DOI: 10.5593/sgem2017H/63/S25.015

ANXIOLYTIC-LIKE EFFECTS OF BIOTECHNOLOGICAL PREPARATION ROPREN® IN β-AMYLOID-(25-35) RAT MODEL OF ALZHEIMER’S DISEASE IN FEMALE RATS WITH EXPERIMENTAL MODEL OF MENOPAUSE

J. Fedotova, O. Volkova
Thursday 23 November 2017 by Libadmin2017

References: 17th International Multidisciplinary Scientific GeoConference SGEM 2017, www.sgemviennagreen.org, SGEM2017 Vienna GREEN Conference Proceedings, ISBN 978-619-7408-29-4 / ISSN 1314-2704, 27 - 29 November, 2017, Vol. 17, Issue 63, 117-124 pp; DOI: 10.5593/sgem2017H/63/S25.015

ABSTRACT

The global population of menopausal women is on the rise and expected to increase from 470 million in 1990 to 1.2 billion by the year 2030. Most of them suffer from postmenopausal symptoms, such as hot flushes, tender breasts, vaginal dryness, reduced bone mineral density, cognitive deterioration and neuropsychiatric disorders such as different mood disturbances and cognitive impairments including Alzheimer’s disease (AD). Considering the wide use of complementary and alternative medications such as bioactive supplements in menopausal patients and our insufficient knowledge about the interaction between hormone replacement therapy and bioactive supplements, investigating the subject from a preclinical experimental studies seems very beneficial. Ropren® can be such candidate substance for treatment of AD in women with an imbalance of estrogen. Ropren® substance (pure polyprenols) was isolated from the green verdure of Picea abies (L.) Karst. Nowadays, polyprenols have been extensively studied as multifunctional agents for the prevention and treatment of many neurological diseases. The present preclinical study was designed to examine the effects of prolonged Ropren® administration (8.6 mg/kg, per os, 28 days, once daily) on anxiety-like behavior in a β-amyloid (25-35) rat model of Alzheimer’s disease following long-term ovariectomy (12 weeks). The experimental model was created by intracerebroventricular injection of β-amyloid (25-35) into ovariectomized (OVX) rats and OVX rats with 17β-estradiol (17β-E2, 5.0 μg/rat, subcutaneously, once daily, 28 days) supplementation. Ropren® was administered to the OVX rats and OVX rats treated with 17β-E2. Anxiety-like behavior was assessed in the elevated plus maze and light-dark test (LDT), as well a spontaneous locomotor activity was assessed using the open field test. The corticosterone and estradiol levels in the blood serum before and after EPM and LDT tests were measured in all experimental groups. Treatment with Ropren® significantly increased the time spent into the open arms of OVX rats with β-amyloid (25-35)-induced amnesia in the EPM and LDT tests. Co-administration of Ropren® with 17β-E2 exerted a markedly synergistic anxiolytic-like effect in the OVX rats with β-amyloid (25-35)-induced amnesia on the same models of anxiety-like behavior testing. Ropren® administered alone or together with 17Β-E2 significantly enhanced crossing, frequency of rearing and grooming of the OVX rats with β-amyloid (25-35)-induced amnesia in the open field test. Moreover, Ropren® administered alone or together with 17β-E2 significantly increased lower estradiol levels in the blood serum of OVX rats with β-amyloid (25-35)-induced amnesia. These results indicate that Ropren® has a marked anxiolytic-like effect in the experimental model of Alzheimer’s disease in female rats with long-term estrogen deficiency.

Keywords: Alzheimer’s disease, polyprenols, Ropren®, anxiety, ovariectomy, estradiol

PAPER DOI: 10.5593/sgem2017H/63/S25.015, ANXIOLYTIC-LIKE EFFECTS OF BIOTECHNOLOGICAL PREPARATION ROPREN® IN β-AMYLOID-(25-35) RAT MODEL OF ALZHEIMER’S DISEASE IN FEMALE RATS WITH EXPERIMENTAL MODEL OF MENOPAUSE

35 EURO ADD TO CART


Your cart ( items)

Subtotal:
Tax cost ():
Shipping cost:
Total:
Checkout Empty